The clinical record on AOD-9604 documents a compound that looked far stronger in animals than it did in people. AOD-9604 is a synthetic fragment of human growth hormone that Metabolic Pharmaceuticals developed as an anti-obesity candidate, but its pivotal human trial failed to beat placebo, and no major regulator has approved it as a weight-loss medicine. The evidence that remains is thin and weighted toward preclinical work rather than controlled human proof.
Clinical research shows AOD-9604's positive animal weight-loss data did not carry into humans, its pivotal Phase 2b obesity trial found no meaningful advantage over placebo, and the compound has never been approved as a weight-loss medicine by any major regulator.
The Phase 2b program is where AOD-9604's obesity ambitions effectively ended. The trial was randomized and placebo-controlled in overweight and obese adults, testing several oral dose levels against placebo over roughly several months, and the reductions in the active arms were not meaningfully greater than the reduction seen with placebo. There was also no convincing dose-response pattern, one of the signals investigators rely on to separate a real drug effect from noise.
AOD-9604's pivotal Phase 2b obesity trial reported no weight loss meaningfully greater than placebo and no convincing dose-response signal, and it did not meet its primary weight-loss endpoint.
The gap between AOD-9604's animal data and its human data is the most instructive feature of its clinical story. In obese rodent models the peptide reduced body weight and adipose tissue and appeared to shift fat metabolism toward breakdown, yet in the controlled Phase 2b human trial that effect essentially did not carry over. Translational failure of this kind is common, because rodents and humans differ in metabolic rate, dosing relative to body size, receptor biology, and the controlled versus free-living conditions under which weight is measured.
| Dimension | Obese rodent models | Human Phase 2b trial |
|---|---|---|
| Body weight | Reduced | No meaningful loss vs placebo |
| Adipose tissue | Reduced | No confirmed reduction |
| Fat metabolism | Shifted toward breakdown | Effect did not carry over |
| Evidence rank | Hypothesis-generating | Controlled human outcome |
In obese rodent models AOD-9604 reduced body weight and fat, but that effect did not carry into humans, where the controlled Phase 2b trial found no weight loss meaningfully beyond placebo.
Development for obesity ended for the most basic reason a drug program can fail: the compound did not work well enough in humans to justify going forward. Once the Phase 2b trial showed no meaningful advantage over placebo, there was no credible path to the efficacy a regulator requires for an anti-obesity approval, and the cost of large Phase 3 trials made continuing indefensible on data that showed no clear effect. The record documents an efficacy-driven decision, not a safety scandal or a funding accident.
Clinical development of AOD-9604 for obesity was discontinued as an efficacy-driven decision after the Phase 2b trial showed no meaningful advantage over placebo, not because of any safety problem.
After obesity was abandoned, AOD-9604 was floated for cartilage repair, joint and tendon health, and general fat-metabolism support, but the evidence behind these ideas is far weaker than the marketing language around them suggests. The available work is small, often uncontrolled, and preclinical or exploratory rather than backed by large randomized human trials, so the claims that circulate in wellness and performance settings rest mostly on mechanism speculation, animal data, or anecdote. No major regulator has approved the peptide for cartilage repair or any other non-obesity indication.
Proposed non-obesity uses of AOD-9604, including cartilage repair, rest on small, uncontrolled preclinical or anecdotal evidence, and no major regulator has approved the peptide for any such indication.
Safety is the one area where AOD-9604 performed acceptably in the trials that were run, though a clean tolerability readout is not evidence of benefit. Across the human obesity trials the peptide was generally reported as reasonably well tolerated, without the marked rises in blood glucose or IGF-1 that accompany full growth hormone, and without dose-limiting toxicity emerging as the central problem. The important limit is that these trials were short and modest in size, so they speak to short-term tolerability and leave long-term exposure, unstudied populations, and delayed effects as open questions.
AOD-9604 was generally reported as well tolerated over the short term without the glucose or IGF-1 effects of full growth hormone, but the trials were short and small, leaving long-term safety unestablished, and tolerability is not evidence of effectiveness.
Judged as a whole, the clinical evidence base for AOD-9604 is thin, dated, and skewed toward animal work rather than human proof. The human record centers on a small number of obesity-program trials, capped by the Phase 2b study whose negative result is the most consequential data point the compound has, and a well-designed trial that finds no benefit counts as evidence against efficacy rather than a neutral gap. The larger volume of encouraging preclinical literature cannot outrank a controlled human outcome that contradicted it.
The clinical evidence base for AOD-9604 rests on a small set of obesity trials capped by a negative pivotal Phase 2b study, and crediting the compound as effective would require new, adequately powered, independently replicated human trials that do not currently exist.
AOD-9604's appeal always rested on a tidy mechanistic story, and its clinical history shows why a tidy mechanism is not the same as a working drug. The peptide is the C-terminal fragment of human growth hormone spanning amino acids 176 to 191 with an added tyrosine, a segment tied to the hormone's fat-metabolizing activity rather than its growth-promoting activity, and it was proposed to raise lipolysis and discourage lipogenesis without meaningfully raising blood glucose or IGF-1. On paper the rationale is coherent, but the pivotal human trial did not convert it into a clinically useful effect.
AOD-9604 was designed as the amino acid 176-191 fragment of human growth hormone to stimulate fat breakdown without raising glucose or IGF-1, but the pivotal human trial showed no meaningful weight loss, so the proposed mechanism did not translate into a clinical effect.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
